We are live on ! Find out more
LWCFA

Loring Wolcott & Coolidge Fiduciary Advisors Portfolio holdings

AUM $10.3B
1-Year Est. Return 3.26%
This Fund
S&P 500
This Quarter Est. Return
+8.83%
1 Year Est. Return
+3.26%
3 Year Est. Return
+43.63%
5 Year Est. Return
+56.22%
10 Year Est. Return
+342.64%
AUM
$11.3B
AUM Growth
+$1.04B
Cap. Flow
-$52M
Cap. Flow %
-0.46%
Top 10 Hldgs %
47.48%
Holding
572
New
12
Increased
35
Reduced
164
Closed
54

Top Buys

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$18.8M
2
SNPS icon
Synopsys
SNPS
+$11.8M
3
TMO icon
Thermo Fisher Scientific
TMO
+$9.22M
4
DKS icon
Dick's Sporting Goods
DKS
+$9.09M
5
VEEV icon
Veeva Systems
VEEV
+$8.73M

Top Sells

Rank Stock Value
1
MA icon
Mastercard
MA
+$22.6M
2
MSFT icon
Microsoft
MSFT
+$10.7M
3
INTU icon
Intuit
INTU
+$7.3M
4
PGR icon
Progressive
PGR
+$5.02M
5
TJX icon
TJX Companies
TJX
+$4.86M

Sector Composition

Rank Sector Weight
1 Technology 40.61%
2 Healthcare 15.23%
3 Consumer Discretionary 10.81%
4 Financials 10.75%
5 Communication Services 7.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SAM icon
476
Boston Beer
SAM
$1.89B
$12K ﹤0.01%
63
AEG icon
477
Aegon
AEG
$13.9B
$11.7K ﹤0.01%
1,610
AMLX icon
478
Amylyx Pharmaceuticals
AMLX
$2.6B
$11.6K ﹤0.01%
1,803
MNST icon
479
Monster Beverage
MNST
$90.1B
$11.2K ﹤0.01%
356
TPZ
480
Tortoise Electrification Infrastructure ETF
TPZ
$127M
$11.1K ﹤0.01%
542
EMN icon
481
Eastman Chemical
EMN
$8.29B
$10.3K ﹤0.01%
138
HLN icon
482
Haleon
HLN
$43.2B
$9.85K ﹤0.01%
950
PCRX icon
483
Pacira BioSciences
PCRX
$945M
$9.56K ﹤0.01%
400
SBAC icon
484
SBA Communications
SBAC
$19.4B
$8.92K ﹤0.01%
38
RUN icon
485
Sunrun
RUN
$2.37B
$8.88K ﹤0.01%
1,086
DGX icon
486
Quest Diagnostics
DGX
$26.2B
$8.62K ﹤0.01%
48
DKNG icon
487
DraftKings
DKNG
$12.7B
$8.58K ﹤0.01%
200
TT icon
488
Trane Technologies
TT
$105B
$7.44K ﹤0.01%
17
COGT icon
489
Cogent Biosciences
COGT
$6.76B
$7.18K ﹤0.01%
1,000
CSGP icon
490
CoStar Group
CSGP
$12.4B
$6.43K ﹤0.01%
80
ZION icon
491
Zions Bancorporation
ZION
$10.5B
$6.23K ﹤0.01%
120
REAL icon
492
The RealReal
REAL
$1.36B
$5.76K ﹤0.01%
1,202
HXL icon
493
Hexcel
HXL
$7.74B
$5.65K ﹤0.01%
100
MPT
494
Medical Properties Trust
MPT
$2.42B
$5.6K ﹤0.01%
1,300
CPRT icon
495
Copart
CPRT
$26.8B
$5.54K ﹤0.01%
113
CC icon
496
Chemours
CC
$2.29B
$5.27K ﹤0.01%
460
NOK icon
497
Nokia
NOK
$57.6B
$5.18K ﹤0.01%
1,000
SPMD icon
498
State Street SPDR Portfolio S&P 400 Mid Cap ETF
SPMD
$19B
$4.89K ﹤0.01%
90
MRNA icon
499
Moderna
MRNA
$25.4B
$4.83K ﹤0.01%
175
SPSM icon
500
State Street SPDR Portfolio S&P 600 Small Cap ETF
SPSM
$17.5B
$4.47K ﹤0.01%
105

Similar funds

Loring Wolcott & Coolidge Fiduciary Advisors's Q2 2025 Portfolio in Review

As of Q2 2025, Loring Wolcott & Coolidge Fiduciary Advisors held 572 positions worth $11.3B, up 10% from $10.3B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Loring Wolcott & Coolidge Fiduciary Advisors's Q2 2025 filing shows 12 new, 35 increased, 164 reduced and 54 closed positions. Its largest new stake was Capital One: 17,701 shares worth $3.77M. The largest sale was Mastercard, an estimated $22.6M.

By sector, the portfolio is most concentrated in Technology at 41% of assets, up from 39% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • Loring Wolcott & Coolidge Fiduciary Advisors's largest Q2 2025 buy was Capital One: 17,701 shares worth $3.77M.
  • Loring Wolcott & Coolidge Fiduciary Advisors added most to NVIDIA in Q2 2025, an estimated $18.8M increase.
  • Loring Wolcott & Coolidge Fiduciary Advisors's biggest Q2 2025 reduction was Mastercard, cutting an estimated $22.6M.
  • Loring Wolcott & Coolidge Fiduciary Advisors fully exited Discover Financial Services in Q2 2025, selling an estimated $3.31M.
  • Loring Wolcott & Coolidge Fiduciary Advisors's ten largest holdings make up 47% of its $11.3B portfolio in Q2 2025.
  • Loring Wolcott & Coolidge Fiduciary Advisors opened 12 new positions and closed 54 in Q2 2025.
  • Loring Wolcott & Coolidge Fiduciary Advisors's portfolio value rose 10% quarter-over-quarter to $11.3B.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2025, filed 30 Jul 2025.